



Coliprotec F4

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary ⁴
R/0005	Renewal of the marketing authorisation.	07/11/2019	15/01/2020	SPC, Annex II, Labelling and PL	The European Commission renewed the marketing authorisation for Coliprotec F4.
IB/0002	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	22/12/2015	28/09/2016	SPC	The Agency accepted the variation to increase the shelf-life of the finished product from 15 months to 18 months.
IB/0001	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	23/09/2015	28/09/2016	SPC	The Agency accepted the variation to extend the shelf-life of the finished product from 1 year to 15 months.

¹ Notifications are issued for type I variations (unless part of a group including a type II variation or higher procedure or a worksharing application). Opinions are issued for all other procedures.

² A CD is issued for procedures that affect the terms of the marketing authorisation (e.g. SPC, Annex II, Labelling, PL). The CD is issued within 2 months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within 1 year for other procedures.

³ SPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

⁴ Since October 2019 summary information is no longer published for quality variations that do not impact upon the product information

